{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:07:41Z","timestamp":1795208861565,"version":"4.10.3"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,11]]},"abstract":"<jats:p>Large-scale vaccination against the spread and mutation of COVID-19 is being implemented in many countries. We aimed to assess the effectiveness of certain vaccines (87.35% inactivated), mainly Sinovac \u2013 CoronaVac and Sinopharm (Beijing) \u2013 BBIBP-CorV, during the Omicron BA.2 pandemic by cross-sectional study. The study was conducted in a cabin hospital of Shanghai, China. A total of 1194 Covid-19 patients infected with Omicron BA.2 were enrolled and epidemiological survey information was collected from the subjects through electronic medical records and questionnaires, from March 23th to April 1st in 2022. Vaccine effectiveness was reflected by the occurrence of multi-dimensional symptoms while adjusting for confounding variables. In the unstandardized vaccinated group, the Covid-19 vaccine effectiveness of Omicron BA.2 in the male group was higher than in the female group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0171). In the standardized vaccinated group, vaccine effectiveness in [20, 40) age group was higher than in other age groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0002). Adjusting for gender and age, Covid-19 vaccine effectiveness of Omicron BA.2 at the specific level was 87.42% (95% confidence interval [CI], 72.35\u201394.28, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.0001), and 62.65% (95% CI, 1.47\u201385.84, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.047) in the unstandardized vaccinated and the standardized vaccinated group, respectively. Covid-19 vaccine effectiveness of Omicron BA.2 was not apparent at the general level but remained effective for the specific symptom. Further development for the Covid-19 vaccine is necessary.<\/jats:p>","DOI":"10.1097\/md.0000000000031763","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:06:32Z","timestamp":1668693992000},"page":"e31763","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Covid-19 vaccine effectiveness during Omicron BA.2 pandemic in Shanghai: A cross-sectional study based on EMR"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-6041","authenticated-orcid":false,"given":"Site","family":"Xu","sequence":"first","affiliation":[{"name":"Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Sun","sequence":"additional","affiliation":[{"name":"Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar.","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1056\/NEJMoa2116063","article-title":"COVID-19 vaccine effectiveness in New York state.","volume":"386","author":"Rosenberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbrc.2020.10.102","article-title":"Evolution patterns of SARS-CoV-2: snapshot on its genome variants.","volume":"538","author":"Giovanetti","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1073\/pnas.97.13.6967","article-title":"The evolution of RNA viruses: a population genetics view.","volume":"97","author":"Moya","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile.","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-20250504","first-page":"4","article-title":"Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.","volume":"37","author":"Ranzani","year":"2021","journal-title":"BMJ"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M21-3509","article-title":"Effectiveness of inactivated COVID-19 vaccines against COVID-19 pneumonia and severe illness caused by the B.1.617.2 (Delta) variant: evidence from an outbreak in Guangdong, China.","volume":"175","author":"Kang","year":"2022","journal-title":"Ann Int Med"},{"key":"R19-20250504","first-page":"2009","article-title":"Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China.","volume":"2021","author":"Hu","year":"2021","journal-title":"medRxiv"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","article-title":"Global impact of varicella vaccination programs.","volume":"15","author":"Varela","year":"2019","journal-title":"Human Vacc Immunother"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-022-04466-x","article-title":"Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants.","volume":"603","author":"Wang","year":"2022","journal-title":"Nature"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:03:25Z","timestamp":1746335005000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":14,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031763","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}